Investor Presentaiton
Investor presentation
Full year 2018
Slide 34
Million
Region China at a glance
Diabetes trend in population
Population with diabetes
Diabetes growth rate
Diabetes market by value and
Novo Nordisk market share
Novo Nordisk reported sales
160
NN Insulin MS
NN OAD MS
bDKK
24
NN GLP-1 MS
Full year 2018
Sales
(mDKK)
Growth2
100%
Long-acting insulin³
814
20%
495%
7%
Premix insulin4
3,783
9%
GLP-1 - 80%
120
|
Fast-acting insulin5
1,450
18%
125
33.6%1
117
16
Human insulin
2,821
(7%)
60%
Total insulin
80
8,868
6%
12.1%¹
Insulin
40%
GLP-16
521
73%
8
00
40
I
20
0
0
2000
2017
2045
Nov
2013
12.6%1
OAD
20%
Other diabetes care?
Diabetes care
1,672
10%
11,061
8%
Obesity (SaxendaⓇ)
1
0%
Biopharm³
223
(2%)
Nov
2018
Total
11,285
8%
China population 2018: ~1.4 billion people and diabetes prevalence
~10.9%
Source: International Diabetes Federation: Diabetes Atlas 1th Edition
2000 and Diabetes Atlas 8th Edition 2017
1 CAGR calculated for last 5-year period
Competitor value market share comparison for insulin as of Nov 2018:
Novo Nordisk 48%, Sanofi 18%, GanLi 12% and Eli Lilly 11%
Competitor value market share comparison for GLP-1 as of Nov 2018:
Novo Nordisk 87% and AstraZeneca 12%
OAD: Oral anti-diabetic; MS: Market share
Source: IQVIA MAT Nov, 2018 value figures
2 Percentage change in local currency from full year 2017 to full year
2018
3 Comprises TresibaⓇ and Levemir®: 4 Comprises NovoMix®;
5 Comprises NovoRapid®; 6 Comprises VictozaⓇ; 7 Comprises NovoNorm®
and needles; 8 Comprises primarily NovoSeven®, Novo Eight® and
NorditropinⓇView entire presentation